Best Pharmaceuticals for Children Act (BPCA) Pediatric Trials Network (PTN)

The National Institutes of Health National Institute of Child Health and Development intends to award an indefinite delivery indefinite quantity contract to design, conduct, and oversee clinical, scientific, and technical aspects of pediatric drug development including pre-clinical studies, formulations development, and Phase 1-3 pediatric clinical trials under the Best Pharmaceuticals for Children Act Pediatric Trials Network. Interested small businesses must demonstrate experience managing multiple concurrent pediatric clinical trials, developing pediatric formulations, coordinating clinical trial activities, conducting trials in accordance with Good Clinical Practice standards, and statistical analysis by January 18, 2024 to be considered for the potential eight-year contract award.

There is no set-aside designated for this procurement. The main NAICS code is 541715 and PSC code is R425. The contract will support an indefinite delivery indefinite quantity of clinical, scientific, and technical services over eight years. Interested parties must submit capability statements by January 18, 2024 for consideration.